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a b s t r a c t
Adrenergic receptors are a key component of nanoscale multiprotein complexes that are responsible for
controlling the beat rate in a mammalian heart. We demonstrate the ability of near-field scanning optical
microscopy (NSOM) to visualize b2-adrenergic receptors (b2AR) fused to the GFP analogue Venus at the
nanoscale on HEK293 cells. The expression of the b2AR-Venus fusion protein was tightly controlled using
a tetracycline-induced promoter. Both the size and density of the observed nanoscale domains are depen-
dent on the level of induction and thus the level of protein expression. At concentrations between 100
and 700 ng/ml of inducer doxycycline, the size of domains containing the b2AR-Venus fusion protein
appears to remain roughly constant, but the number of domains per cell increase. At 700 ng/ml doxycy-
cline the functional receptors are organized into domains with an average diameter of 150 nm with a
density similar to that observed for the native protein on primary murine cells. By contrast, larger
micron-sized domains of b2AR are observed in the membrane of the HEK293 cells that stably overexpress
b2AR-GFP and b2AR-eYFP. We conclude that precise chemical control of gene expression is highly advan-
tageous for the use b2AR-Venus fusion proteins as models for b2AR function. These observations are crit-
ical for designing future cell models and assays based on b2AR, since the receptor biology is consistent
with a relatively low density of nanoscale receptor domains.
! 2009 Elsevier Inc. All rights reserved.
Introduction
The beating rate in the mammalian heart is strongly influenced
by the binding of catecholamines to b-adrenergic G-protein cou-
pled receptors (bARs) in cardiac myocytes, initiating an adrenergic
response [1–3]. The signaling cascade initiated by catecholamine
binding requires the association of bARs into multiprotein com-
plexes called signalosomes [4] that include the a, b and c G-protein
subunits. Changes in the molecular composition of signalosomes
are associated with receptor desensitization, sequestration of the
receptor to subcellular membranous compartments and internali-
zation, all of which strongly influence bAR function [5–11]. Signal-
ing has also been shown to depend on differential interactions with
scaffolding proteins in signaling complexes [12]. Recently we have
used near field scanning optical microscopy (NSOM) to demon-
strate that functional receptors are organized into multi-protein
domains of !140 nm average diameter on murine neonatal and
embryonic cardiac myocytes [13]. Colocalization experiments in
these primary cells at the nanometer scale show that 15–20% of
receptors are pre-associated in caveolae, an important component
of signalosomes [13]. bAR signaling represents an important phar-
macological target [14] and many assays have been developed to
aid in the drug discovery process [15–18]. Herein we investigate
the conditions required for mimicking the nanoscale distributions
and local environment observed in primary cells from the mamma-
lian heart using a conditionally expressed fusion protein of b2AR in
HEK293 cells.
Fusion proteins of bARs have provided useful tools for studies of
adrenergic receptor biology and the development of assays for li-
gand discovery based on bioluminescence and Forster resonance
energy transfer (BRET and FRET, respectively) [2,15–24]. Func-
tional fusion proteins of b2ARs have been accomplished with FLAG
tags for immunofluorescence and immunoprecipitation experi-
ments as well as green fluorescent proteins (GFPs) and their ana-
logues [15–18,25]. Inducible expression of GPCRs has also been
achieved allowing for precise chemical control of expression levels
in mammalian cells [26,27]. We have adapted one of the human
b2AR-GFP fusion proteins to contain the ‘‘Venus” yellow fluores-
cent protein which was optimized for biophysical studies [28].
We placed the human b2AR-Venus fusion protein under tetracy-
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cline-dependent expression using the ‘‘Tet-On” system in order to
have precise chemical control of membrane protein expression so
that we could correlate expression levels with nanoscale clustering
on the cell surface.
Materials and methods
Cell culture. HEK 293 cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented
with 10% fetal bovine serum (FBS) (NorthBio, Toronto, ON), penicil-
lin (100 IU/ml), and streptomycin (100 mg/ml) (Invitrogen) under
standard culture conditions (37 "C, 5% CO2). The HEK 293Tet-On
cells, which stably express the reverse transactivator (rTA) from
the Tet-On inducible system, were grown in complete DMEM with
800 lg/ml G418 (Invitrogen). The b2AR FRET cells stably express-
ing b2AR-GFP2 and b2AR-eYFP were grown in DMEM supplemented
with 10% FBS, penicillin (100 IU/ml), streptomycin (100 mg/ml),
300 lg/ml G418 and 300 lg/ml Zeocin (Invitrogen) under standard
culture conditions (37 "C, 5% CO2).
Eukaryotic expression vector. The pTREb2AR-Venus construct was
created by cutting out the b2-adrenergic receptor coding sequence
including the stop signal from pRL-CMV-b2AR-RLuc, which was a
generous gift of Dr. Bouvier (Université de Montréal), using the
NheI restriction enzyme. It was then subcloned in pTREhyg, sup-
plied in the BDTM Tet-on gene expression system kit (Clontech Lab-
oratories Inc, Mountain View, CA), in the NheI site. The Venus
coding sequence was amplified by Polymerase Chain Reaction
(PCR), using pVS1 plasmid, which was a generous gift of Dr. Xie
(Harvard University) as a template. The restriction sites NotI and
SalI were added, respectively, to the C- and N-terminus of Venus.
The reverse primer sequence was TATTGTCGACTTACTTGTAC
AGCTCGTCC and the forward primer sequence was ATAATAAAG
CGGCCGCTAATGGTGAGCAAGGGCG. The Venus gene was then sub-
cloned in frame with b2AR in the pTREhyg backbone. The pb2AR-
GFP2 construct was created by cutting out the b2AR coding se-
quence as described earlier and it was then subcloned in pGFP2-
N3 (PerkinElmer Life and Analytical Sciences, Boston, MA). The
pb2AR-eYFP construct was a generous gift of Dr. Bouvier (Univer-
sité de Montréal).
Inducible system. The BDTM Tet-on gene expression system kit
was used to express wild type b2AR fused to Venus, an YFP variant
in HEK 293 cells under the control of a doxycycline inducible pro-
Fig. 1. Fluorescence microscopy images of (A) L9 (HEK293Tet-On) cells not treated with Dox; (B) L9 cells transiently transfected with b2AR-Venus gene but not treated with
Dox; (C) L9 cells transfected with b2AR-Venus gene and treated with 100 ng/ml Dox; (D) L9 cells transfected with b2AR-Venus gene and treated with 700 ng/ml Dox with scale
bars representing 10 lm; (E) Western blot of the immunoprecipitated b2AR-Venus at various Dox concentrations.
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moter. The HEK 293Tet-on cell line was developed from wild-type
HEK 293 cells by transfection with the regulator pTet-On plasmid
(5 lg) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA), as in-
structed by the manufacturer. Colonies were isolated and trans-
ferred into 10 cm tissue culture dishes in the presence of 800 lg/
ml of G418 in complete DMEM. G418-resistant clones were ex-
panded and screened by luciferase assay using the pTRE2hyg-Luc
reporter plasmid, which expresses a luciferase gene under the con-
trol of the tetracycline-response element (TRE).
Imaging of fixed cells. To examine the effect of different doxy-
cycline (Dox) concentrations on the expression level of b2AR-Ve-
nus, Lab-Tek II 8-well chambered slides (Nalgene Nunc,
Rochester, NY) were seeded with HEK 293Tet-on cells. The cells
were then transfected with 0.1 lg pTREb2AR-Venus plasmid per
well. Four hours post-transfection growth media with 20% FBS
was added and the cells were allowed to recover for 24 h. Fol-
lowing the 24 h recovery period the media was replaced with
growth media with or without varying concentrations of Dox
to induce expression of b2AR-Venus. Twenty-four hours post-
induction the cells were washed once with 1" PBS pH 7.4, fixed
with 3.7% formaldehyde for 30 min at 4 "C and washed 3 times
with 1" PBS to remove the excess formaldehyde. Slides were
cover slipped using anti-fade mounting medium (pH 8.0; 1 mg
p-phenylendiamine, PBS, 90% glycerol). Imaging was done on
an Olympus IX81 microscope using the Olympus Plan Apochro-
mat 60", 1.45 NA oil immersion objective and the Blue Argon
(488 nm) laser. Images were captured using a Cool Snap ES cam-
era (Roper Scientific Photometrics, Tucson, AZ).
Fig. 2. Representative NSOM images of (A) HEK293Tet-On cells transfected with b2AR-Venus and treated with 700 ng/ml of Dox, (B) control HEK293Tet-On cells, not treated with
Dox, (C) cardiac myocytes with immuno-labeled b2AR, and (D) HEK293 cells stably expressing b2AR-eYFP and b2AR-GFP2; a1, b1, c1 and d1 show topography with scale bars
at 5 lm; a2, b2, c2 and d2 are matching fluorescence images of the same area; a3, b3, c3 and d3 are zoom-in images corresponding to the white squares in a2, b2, c2 and d2
with scale bars of 2 lm and intensity scales of 30 kcounts/s.
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NSOM. Bent NSOM probes were prepared from high GeO2-
doped fibers with a core diameter of 3 lm via a two-step chemical
etching method followed by aluminum deposition and focused
ion-beam milling to produce a flat circular aperture [29]. The
probes used in the present work had aperture diameters of roughly
100 nm (estimated from SEM images and by imaging 40-nm dye-
labeled polymer microspheres). The estimated spring constant
for these probes is !100 Nm#1 [29]. NSOM experiments were car-
ried out on a combined AFM/NSOM microscope based on a Digital
Instruments Bioscope mounted on an inverted fluorescence micro-
scope (Zeiss Axiovert 100). Cellular imaging was carried out using
488 nm excitation. The NSOM cellular imaging procedure is de-
scribed in detail previously [13,30].
For experiments in which the effect of Dox concentration was
examined in HEK293 cells, at least three different 40 " 40 lm2
areas and three 10 " 10 lm2 areas were imaged for each sample
at a constant laser power. HEK293 cells expressing b2AR-GFP2
and b2AR-eYFP were imaged with a probe with a similar aperture
diameter, but required significantly lower laser excitation intensity
to achieve similar NSOM fluorescence signals. We verified that the
NSOM probe aperture remained unchanged throughout the exper-
iments by scanning 40 nm fluorescent spheres before and after the
experiments. Cluster size analysis was performed using original
non-processed NSOM images with custom-made software that
determines the number of clusters and their location in the image,
as well as their full width at half maximum and maximum inten-
sity, as previously described [13,30]. Images shown in the Support-
ing information demonstrate the ability of the software to
accurately count most of the clusters; however, there are some dif-
fuse patches of fluorescence which cannot be distinguished from
the background. Representative histograms of cluster size for L9
cells transfected with the b2AR-Venus gene and treated with 100
and 700 ng Dox are shown in Fig. 3. Note that the smallest feature
size is limited by the size of the probe aperture used; cluster sizes
reported represent a convolution of probe aperture and feature
size. The total intensities for individual clusters were calculated
from the cluster diameter and maximum intensity, assuming a
Gaussian-shaped intensity profile.
Results and discussion
We created a stable cell line containing the reverse tetracycline-
controlled transactivator (rtTA) gene, carefully selecting a clone
that had the lowest background expression and best sensitivity
from a response plasmid which expressed luciferase under control
of the tetracycline-response element (TRE) when treated with
doxycycline (Dox) (see Fig. S1, supporting information). This al-
lowed us to have precise chemical control of the expression levels
Fig. 3. Representative NSOM fluorescence images of (A) control L9 cells (HEK293Tet-On) transfected with the response plasmid containing b2AR-Venus but not treated with
Dox, (B) L9 cells expressing b2AR-Venus upon treatment with 100 ng/ml Dox, (C) L9 cells expressing b2AR-Venus treated with 700 ng/ml Dox. Scale bars correspond to 2 lm,
and the vertical range is 20 kcounts/s. The histograms in (D,E) show cluster size distributions for images (B,C), with average cluster widths of 130 and 150 nm, respectively.
Note that the measured cluster widths represent a convolution of probe aperture and feature size. Histogram (F) shows the distribution of total integrated fluorescence
intensity for the individual clusters in image (C), with the last bin representing clusters of intensity >500. If we assume that the least intense clusters in the first bin represent
b2AR-Venus receptor dimers then estimates of 10 and 30 proteins for clusters of average and maximum intensity are obtained.
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of the b2AR-venus fusion protein which was also placed in a re-
sponse plasmid under TRE control in HEK293 cells stably transfec-
ted with the rtTA gene (L9 clone). Using fluorescence microscopy
and Western blotting techniques, we established the tight control
over b2AR-Venus fusion protein expression (Fig. 1). The fluores-
cence images and western blot results confirm that the b2AR-Ve-
nus fusion protein is not expressed in untreated cells; the
expression level is low at 100 ng/ml Dox but increases steadily as
the Dox concentration is increased to 700 ng/ml. Using ELISA as-
says on intact cells we show that at 700 ng/ml of Dox the b2AR-Ve-
nus protein is present at approximately the same physiologically
relevant levels on the L9 clone as those on H9C2 rat cardiac myo-
cyte cells (Fig. S2, supporting information). We observed that there
was significant endogenous b2AR expression in the L9 clone, !40%
relative to the H9C2 cells; however, these are not fluorescent.
We used NSOM to investigate the expression of b2AR on L9
(HEK293Tet-On) cells that were transfected with the response plas-
mid containing b2AR-Venus fusion protein at various concentra-
tions of the inducer Dox. Using !100 nm diameter aperture bent
fiber NSOM probes operating in the tapping modeTM and fluores-
cence microscopy, we examined the intensity and distribution of
b2AR-Venus (Fig. 2). We observed distinct fluorescent patches on
the surfaces of cells at Dox concentrations between 100 and
800 ng/ml, with fluorescence signals increasing in a similar trend
to the level of protein expression shown in Fig. 1. Representative
NSOM topography and fluorescence images are shown in Fig. 2A
for cells treated with 700 ng/ml Dox. The b2AR-Venus is localized
in many small clusters on the cell surface. Control experiments
in which cells that were not transfected or were transiently trans-
fected but not treated with Dox gave much lower signal intensities,
as illustrated by the images shown in Fig. 2B for untransfected and
untreated cells. Note that the larger image in Fig. 2b2 shows sev-
eral diffuse patches of fluorescence that correlate with higher re-
gions in the topographic scan (Fig. 2b1). However, the low signal
intensity in the zoomed fluorescence image (Fig. 2b3) indicates
minimal signal due to either background fluorescence or topogra-
phy-related artifacts [13]. An additional control experiment for
untransfected cells that were treated with 700 ng/ml Dox did not
show a significant level of fluorescence signal (Fig. S3, supporting
information).
The receptor distribution for cells treated with 700 ng/ml Dox is
qualitatively similar to our previous observations of bAR localiza-
tion within nanodomains in primary cells, as illustrated by the
NSOM images for immunostained b2AR in cardiac myocytes
(Fig. 2C). However, both of these results differ significantly from
the NSOM images for cells stably overexpressing b2AR-GFP2 and
b2AR-eYFP in HEK293 cells (Fig. 2D), which show large diffuse
patches of fluorescence, rather than small nanoscale clusters. As
noted above, ELISA assays conducted on intact cells indicate that
the levels of receptor at the cell membrane for cells treated with
700 ng/ml Dox are quantitatively similar to those on H9C2 cardiac
myocytes where bARs are localized within nanodomains. By con-
trast, HEK293 cells stably overexpressing b2AR-GFP2 and b2AR-
eYFP display at least 4-fold higher expression (Fig. S2, supporting
information). Similarly, we have observed very large patches for
other overexpressed GFP-fused receptors by NSOM rather than
small clusters, further highlighting the importance of the develop-
ment of inducible systems for the study of membrane protein bio-
chemistry at the nanoscale.
Next we analyzed the cluster size and density of b2AR-Venus fu-
sion proteins at low and high concentrations of Dox utilizing meth-
ods described previously [13,30]. The cluster densities increased
with increasing Dox concentration as shown by the images in
Fig. 3A–C for transfected cells treated with 0, 100, and 700 ng/ml
Dox. Supplementary Fig. S4 shows images in which all counted
clusters are marked for the Dox treated cells; note that the data
in Fig. 3C are displayed so that small weak clusters are visible,
whereas at larger intensity scales it becomes evident that some
of the larger features in the upper right corner of the image repre-
sent several smaller clusters. At 700 ng/ml Dox the sizes for the
small roughly circular clusters vary in diameter from 100 nm to
!280 nm with an average of 150 nm (Fig. 3C and E) and the cluster
density is 1.4 features/lm2. The cluster size for 100 ng/ml Dox
(Fig. 3B and D) is similar (average of 130 nm) but the cluster den-
sity is considerably lower at 0.4 features/lm2. Note that there are
also some areas of weak, diffuse signal at the lower Dox concentra-
tion that resemble the background observed in the untreated cells
(Fig. 3A). The similar cluster size observed for high and low cluster
densities indicates that there may be a biological preference for
localization of b2AR receptors in !150 nm diameter domains or
clusters. The measured cluster density of 1.4 features/lm2 for cells
treated with 700 ng/ml Dox is similar to the value of !1.0 features/
lm2 observed for b2AR on H9c2 cells as well as primary murine
cells [13,30].
The clusters of b2AR-Venus have a range of intensities as shown
by the histogram in Fig. 3F. By making the assumption that the
clusters with the lowest total integrated intensity correspond to
b2AR dimers, we estimate that the clusters in Fig. 3C contain from
2 to !60 individual b2AR-Venus proteins; clusters with an average
total intensity correspond to!10 proteins. Because we observe sig-
nificant levels of background b2AR expression in the HEK293Tet-On
cells, we cannot rule out that these features are made up of mixed
receptor types (i.e. both b2AR and b2AR-Venus). Evidence from pre-
vious studies suggests that b2ARs translocate to the cellular mem-
brane as dimers [31,32], although recently it has been
demonstrated that monomeric GPCRs can activate G proteins
[20]. If, in fact the lowest intensity features represent b2AR mono-
mers then the estimates of individual proteins in Fig. 3 will range
from 1 to !30 b2AR-Venus proteins. These estimates are also sim-
ilar to our previous estimates of 12–72 receptors/cluster for clus-
ters ranging in diameter from 120 to 160 nm in immunostained
primary cells [13,30].
Conclusions
In summary, we have demonstrated that NSOM fluorescence
imaging of b2AR-Venus fusion membrane proteins is possible.
Further we show that precise chemical control of receptor
expression is highly advantageous to study the spatial and tem-
poral localization of the receptor on the surfaces of mammalian
cells. We observed that the cluster size and density and the
numbers of receptor/cluster for b2AR-Venus in the ‘‘Tet-On”
inducible system are very similar to our previous observations
for immunostained b2AR in primary neonatal cells. This suggests
that the inducible expression system gives a receptor distribu-
tion that is representative of the physiological state of the recep-
tors on primary cells. The number of membrane protein clusters
can be controlled using different Dox concentrations. However, it
appears that the average size of clusters remains roughly con-
stant with increasing Dox concentrations even though the num-
ber and density of clusters increase. The latter suggests that
there is a strongly preferred membrane local environment for
the b2AR at physiological protein expression levels. This is an
important consideration for the design of new assays for b2AR
function.
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